References
Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D (2018) Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung 196(5):517–530
Chupp GL, Bradford ES, Albers FC et al (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5(5):390–400
Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371(13):1189–1197
Castro M, Zangrilli J, Wechsler ME et al (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3(5):355–366
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors are employees and own shares of GSK.
Rights and permissions
About this article
Cite this article
Gunsoy, N.B., Bratton, D.J. & Alfonso-Cristancho, R. Methodological Concerns of a Recent Network Meta-analysis Assessing Biologics for Eosinophilic Asthma. Lung 197, 105–106 (2019). https://doi.org/10.1007/s00408-018-0183-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-018-0183-x